How to Evaluate a Digital PSP Platform in Saudi Arabia: An RFP-Ready Checklist

How to Evaluate a Digital PSP Platform in Saudi Arabia: An RFP-Ready Checklist

Selecting the right digital patient support program platform is one of the highest-stakes technology decisions a pharmaceutical brand team or procurement committee makes in Saudi Arabia. The wrong choice means months of remediation, regulatory exposure, and—more importantly—patients who do not receive the support they enrolled for. This guide gives procurement teams, PSP leads, and medical affairs directors the structured framework they need to evaluate vendors with confidence, before a pilot begins rather than after it ends.

---

Key Takeaways

• Saudi Arabia's PSP regulatory environment is shaped by SFDA pharmacovigilance requirements, the Personal Data Protection Law (PDPL), and Vision 2030 digital health priorities; every evaluation criterion connects to at least one of these.
• The highest-risk procurement mistake is selecting a platform for its interface and discovering too late that its adverse event (AE) capture, data hosting, or reporting infrastructure cannot meet Saudi requirements.
• A weighted scorecard across ten domains—not an unstructured demo walkthrough—gives procurement committees an auditable, defensible vendor comparison.
• Platform selection and operator selection are separate decisions; this checklist covers the technology layer.
• Keywords are unvalidated editorial hypotheses (H); no search volume claims are made.

---

Platform vs. Service: The Decision That Precedes the Checklist

Before evaluating any vendor, procurement teams must resolve a foundational question: are you sourcing a technology platform (which your internal team or a contracted operator will run), a fully managed service (where the vendor both provides the platform and operates the program), or a hybrid? The answer determines which evaluation criteria are mandatory versus advisory.

This checklist is scoped to platform evaluation—the technology layer. If the vendor bundles operations, apply the criteria here to the technology components of their offering and use separate criteria for the service elements. Conflating the two is the most common cause of scope misalignment in Saudi PSP procurement.

---

Ten Evaluation Domains

Domain 1: Patient Journey Workflow Configurability

Core questions: Can the platform model disease-specific workflows without custom code? Does it support multi-step, conditional enrollment pathways, including those requiring HCP verification or pre-authorization? Can it be reconfigured for a new therapy without a full redevelopment cycle?

What a credible response includes: A working demonstration of a configured workflow in the platform's sandbox environment—not a slide. Evidence that at least one Saudi or GCC therapy workflow is currently live or in validation.

Domain 2: Pharmacovigilance and AE Capture

Core questions: Does the platform systematically prompt users (patients, nurses, coordinators) to report potential adverse events at every interaction touchpoint? Is AE data timestamped, source-attributed, and exportable in a format compatible with SFDA safety reporting requirements? Does the platform maintain an auditable reconciliation log between PSP-captured AEs and the sponsor's global safety database?

What a credible response includes: A live demonstration of the AE capture workflow—not a description of it. The platform should be able to show the exact data fields captured, the trigger logic, the downstream notification pathway, and the reconciliation report format. [VERIFY WITH BRAND — specific SFDA GVP citation references should be reviewed by a Saudi-licensed PV professional.]

Domain 3: PDPL and Data Privacy Architecture

Core questions: Does the platform operate as a data processor under Saudi PDPL, with the sponsor as the data controller? Is health data classified as sensitive data in the platform's data classification model? Can the platform demonstrate documented consent workflows with version-controlled consent templates? Is there a data subject rights management module (access, correction, erasure requests)?

What a credible response includes: A data processing agreement (DPA) template, a data classification policy document, and evidence of consent workflow implementation in the platform. [VERIFY WITH BRAND — PDPL compliance claims should be reviewed by Saudi privacy counsel.]

Domain 4: Data Hosting and Sovereignty

Core questions: Where is patient data hosted? Is in-Kingdom data residency available? Is cross-border data transfer restricted or documented? Does the vendor hold any Saudi or GCC data center certifications?

What a credible response includes: Explicit contractual commitments on data location, not marketing language. If in-Kingdom hosting is claimed, the specific data center and certification should be named. [VERIFY WITH BRAND — hosting architecture claims require technical verification.]

Domain 5: Arabic-Language and Bilingual UX

Core questions: Is Arabic the primary language of the patient-facing interface, or is it a translated version of an English-primary product? Does Arabic RTL layout extend to all clinical workflows, notifications, and PDF outputs, or only the home screen? Can the platform render Arabic numerals where culturally appropriate?

What a credible response includes: A live patient-facing demonstration in Arabic—including an enrollment flow, a medication reminder, and an AE report prompt. Screenshots are insufficient; the evaluator should interact with the Arabic interface directly.

Domain 6: HIS/EMR and Third-Party Integration

Core questions: Does the platform support integration with Saudi hospital information systems, including NPHIES-connected environments? What APIs are available for HL7 FHIR data exchange? Does integration require custom development for each connection, or is there a prebuilt connector library?

What a credible response includes: A published API documentation set and at least one live integration reference in the Saudi market. [VERIFY WITH BRAND — specific integration capabilities require technical validation.]

Domain 7: Sponsor Reporting and Analytics

Core questions: Can sponsors access aggregate reporting without access to identifiable patient data? Is small-cell suppression applied to protect patient privacy in reports? Are reports exportable in sponsor-compatible formats? Is there an audit trail for who accessed which report and when?

What a credible response includes: A demonstration of the sponsor reporting dashboard using de-identified demo data, with explicit explanation of the aggregation rules applied.

Domain 8: Program Governance and Role-Based Access

Core questions: Does the platform enforce role-based access control, ensuring that nurses, coordinators, pharmacists, and sponsor users each have access only to the data appropriate to their role? Is there a full audit log of all data access and modification events? Does the platform support multi-program data segregation for operators running programs for more than one sponsor?

What a credible response includes: A role matrix document and a demonstration of access controls in a configured test environment.

Domain 9: Implementation, Training, and Support

Core questions: What is the typical go-live timeline for a Saudi single-program deployment? Is Arabic-language user training available? Is there a local support presence or only offshore support? What SLA commitments are offered for critical issue resolution?

What a credible response includes: References from at least one Saudi or GCC implementation, a standard implementation timeline, and an SLA document.

Domain 10: Total Cost of Ownership (TCO)

Core questions: What is the pricing model—per patient enrolled, per active patient, per interaction, or platform license? Are there setup, integration, training, or annual maintenance fees separate from the per-patient cost? What are the contractual terms for price changes at renewal?

What a credible response includes: An itemized pricing proposal, not a range. Any pricing that depends on patient volume should be modeled at multiple enrollment scenarios before comparison.

---

Weighted Scorecard

---

Questions to Ask in the Demo

1. "Walk me through what happens from the moment a patient reports a symptom in the app to when it appears in the sponsor's safety reconciliation report."
2. "Show me the Arabic patient enrollment flow on a mobile device—end to end."
3. "What patient data, specifically, can a sponsor user see in the reporting dashboard? Can you show me what they cannot see?"
4. "If we needed to modify the follow-up call workflow for a new indication next year, walk me through what that change process looks like technically."
5. "Show me the data processing agreement template and walk me through which entity is the data controller."

---

FAQ

What is the most important criterion when selecting a PSP platform in Saudi Arabia? Pharmacovigilance and AE capture architecture is the highest-risk criterion because failures in this domain create regulatory and patient safety exposure that cannot be remediated by contract clauses. Evaluate this domain with a live workflow demonstration before any other consideration.

How do we weigh PDPL compliance against functionality when both matter? They are not in tension. A platform that cannot demonstrate PDPL-compliant data architecture is not a viable option regardless of its clinical workflow features. Treat PDPL as a pass/fail threshold, then use the weighted scorecard for the remaining domains.

What PSP data must be hosted inside Saudi Arabia? The PDPL restricts cross-border transfer of personal data and classifies health data as sensitive. While specific implementation requirements should be reviewed with Saudi legal counsel, procurement teams should require vendors to specify their data location contractually, not in marketing materials. [VERIFY WITH BRAND — specific hosting requirements require legal review.]

How should we compare total cost of ownership across vendors with different pricing models? Model all vendors at the same enrollment scenario (your expected Year 1 enrollment, Year 2 active patients, and expected interaction volume). This converts per-patient, per-interaction, and license-fee models into a comparable annual figure. Include integration and training costs in the comparison.

What should a pilot phase prove before full program rollout? A well-designed pilot should demonstrate: (1) AE capture rate and downstream reconciliation function as specified; (2) Arabic interface meets patient usability standards; (3) integration with the sponsor's safety database works without manual intervention; (4) sponsor reporting is accessible and accurate; (5) enrollment and consent workflows comply with local requirements.

---

Published: 2026-11-05 · Author: CareSync Team · This article provides general information for procurement teams evaluating digital PSP platforms in Saudi Arabia. It does not constitute legal, regulatory, or medical advice. All regulatory and compliance claims should be independently verified with qualified advisors.

---

Ready to evaluate CareSync against these criteria? Download the RFP checklist or book a sponsor walkthrough →